Author:
Suichi Tomoki,Misawa Sonoko,Beppu Minako,Takahashi Sho,Sekiguchi Yukari,Shibuya Kazumoto,Amino Hiroshi,Tsuneyama Atsuko,Suzuki Yo-ichi,Nakamura Keigo,Sato Yasunori,Kuwabara Satoshi
Abstract
ObjectiveTo elucidate current epidemiological, clinical profiles, and treatment of polyneuropathy, organomegaly, endocrinopathy, M-protein, and skin changes (POEMS) syndrome.MethodsWe conducted a nationwide survey in 2015 using an established epidemiologic method. Data processing sheets were sent to all neurology and hematology specialist departments throughout Japan to identify patients with POEMS who were seen between April 2012 and March 2015.ResultsThe estimated number of patients with POEMS was 392 (95% confidence interval [CI] 320–464), and the prevalence was 0.3 per 100,000. Detailed clinical profiles were available for 167 patients. Median age at onset was 54 years (range, 21–84 years), and the ratio of male to female was 1.5. All patients showed polyneuropathy; 89% had monoclonal plasma cell proliferation; and 84% had elevated vascular endothelial growth factor level in whom pretreatment serum or plasma was available (n = 87). Other common features were skin changes (84%), edema/effusion (81%), and organomegaly (76%). A total of 160 patients were treated with any of the following: radiation, corticosteroids, melphalan, thalidomide, lenalidomide, bortezomib, or autologous stem cell transplantation. Primary therapeutic options were thalidomide (n = 86) and autologous stem cell transplantation (n = 71). Thirty-nine patients (24%) were initially treated with corticosteroid alone. The 10-year overall survival was 93% (95% CI 86%–96%).DiscussionThis study showed current epidemiologic and clinical status of POEMS syndrome in Japan. A quarter of patients were still inadequately treated with corticosteroid alone, whereas either autologous stem cell transplantation or immunomodulatory drugs improved the prognosis.
Publisher
Ovid Technologies (Wolters Kluwer Health)
Reference38 articles.
1. Greatly raised vascular endothelial growth factor (VEGF) in POEMS syndrome;Watanabe;Lancet,1996
2. Kuwabara S , Dispenzieri A , Arimura K , Misawa S , Nakaseko C . Treatment for POEMS (polyneuropathy, organomegaly, endocrinopathy, M-protein, and skin changes) syndrome. Cochrane Database Syst Rev 2012;CD006828.
3. Plasma cell dyscrasia with polyneuropathy and endocrine disorder: clinical and laboratory features of 109 reported cases;Takatsuki;Jpn J Clin Oncol,1983
4. The Crow-Fukase syndrome: A study of 102 cases in Japan
5. POEMS syndrome: a study of 25 cases and a review of the literatures: French Study Group on POEMS Syndrome;Soubrier;Am J Med,1994
Cited by
42 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献